Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Reports Revenue Slide, Stagnant R&D, Narrowed Net Loss in Q3

NEW YORK, Oct. 24 - Compugen today said that a decrease in third-quarter revenue and stagnant R&D spending helped narrow net loss.


Revenue for the period ended Sept. 30 was $2.8 million, down from $3.1 million reported one year ago, Compugen said. Products and services accounted for $2.4 million of that (a decrease from the third quarter 2001), while income from R&D grants comprised around $460,000 (an increase over the same period last year).


R&D spending was virtually unchanged at $3.5 million, the company said. Still, net loss for the third quarter narrowed to $3.8 million, or $.11 per share, from $4.4 million, or $.14 per share, from the third quarter 2001.


Compugen said it had roughly $59 million in cash, cash equivalents, and short-term investments as of Sept. 30. It had $33.3 million in cash, cash equivalents, and short-term investments as of June 30.


Click here for more information.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.